Latest osteomalacia Stories

MONTREAL, Sept. 15 /PRNewswire/ -- Enobia Pharma, an emerging biotech company focused on developing novel therapeutics for serious bone disorders, presented pre-clinical data demonstrating that its enzyme replacement therapy (ERT) for hypophosphatasia appears to heal bones that have already been severely weakened by the disease. Earlier pre-clinical data showed that ERT with Enobia's product ENB-0040, significantly increases survival and prevents bone hypomineralization associated with...

MONTREAL, Aug. 20 /PRNewswire/ -- Enobia Pharma, an emerging biotech company focused on developing novel therapeutics for serious bone disorders, today announced that the first patient in its clinical program for hypophosphatasia has been dosed. Enobia is investigating Enzyme Replacement Therapy (ERT) with ENB-0040 for the treatment of this rare and often crippling genetic bone disorder for which there is no approved treatment. Under two separate protocols, ENB-0040 will be evaluated in...

SUMMARY Osteomalacia is not rare in the UK and climatically similar countries, particularly in elderly people and those of Asian descent. Overt clinical osteomalacia is usually treated with a loading dose of vitamin D, followed by a regular supplement. However, little is known of the time taken to reach a stable biochemical state after starting treatment. Such information would shed light on the duration of the bone remineralization phase and guide decisions on the length of follow-up. To...